Mirae Asset Global Investments’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.7M Buy
58,746
+18,508
+46% +$3.54M 0.02% 405
2026
Q1
$7.38M Buy
40,238
+5,131
+15% +$945K ﹤0.01% 450
2025
Q4
$6.18M Sell
35,107
-31,903
-48% -$5.21M 0.02% 499
2025
Q3
$9.39M Buy
67,010
+5,987
+10% +$809K 0.03% 384
2025
Q2
$7.66M Buy
61,023
+5,939
+11% +$740K 0.03% 392
2025
Q1
$7.62M Buy
55,084
+7,531
+16% +$1.08M 0.03% 379
2024
Q4
$7.19M Buy
47,553
+4,848
+11% +$818K 0.03% 372
2024
Q3
$8.31M Buy
42,705
+7,510
+21% +$1.57M 0.04% 323
2024
Q2
$8.05M Sell
35,195
-119,133
-77% -$25.9M 0.04% 287
2024
Q1
$39.4M Sell
154,328
-6,396
-4% -$1.5M 0.09% 226
2023
Q4
$41.6M Sell
160,724
-3,719
-2% -$913K 0.08% 229
2023
Q3
$42.3M Buy
164,443
+23,282
+16% +$6.23M 0.09% 209
2023
Q2
$40.2M Sell
141,161
-5,224
-4% -$1.56M 0.09% 229
2023
Q1
$40.7M Sell
146,385
-43,106
-23% -$11.9M 0.09% 218
2022
Q4
$52.5M Buy
189,491
+7,932
+4% +$2.24M 0.14% 173
2022
Q3
$48.5M Buy
181,559
+23,060
+15% +$4.9M 0.13% 170
2022
Q2
$32.3M Buy
158,499
+28,439
+22% +$5.81M 0.08% 273
2022
Q1
$27.4M Buy
130,060
+25,663
+25% +$5.58M 0.06% 344
2021
Q4
$25M Buy
104,397
+18,669
+22% +$4.8M 0.05% 394
2021
Q3
$24.3M Buy
85,728
+16,459
+24% +$5.39M 0.06% 367
2021
Q2
$24M Buy
69,269
+16,014
+30% +$4.85M 0.07% 356
2021
Q1
$14.9M Sell
53,255
-24,445
-31% -$6.59M 0.05% 413
2020
Q4
$19M Buy
77,700
+10,217
+15% +$2.64M 0.07% 325
2020
Q3
$19.1M Buy
67,483
+8,524
+14% +$2.38M 0.1% 251
2020
Q2
$15.8M Buy
58,959
+4,798
+9% +$1.44M 0.1% 241
2020
Q1
$17.1M Buy
54,161
+9,895
+22% +$3M 0.13% 157
2019
Q4
$13.1M Buy
44,266
+6,534
+17% +$1.81M 0.08% 289
2019
Q3
$8.79M Buy
37,732
+1,710
+5% +$398K 0.06% 350
2019
Q2
$8.48M Buy
36,022
+3,525
+11% +$814K 0.06% 334
2019
Q1
$7.65M Buy
32,497
+2,467
+8% +$777K 0.06% 318
2018
Q4
$9.04M Buy
30,030
+2,494
+9% +$796K 0.08% 260
2018
Q3
$9.75M Sell
27,536
-2,173
-7% -$748K 0.07% 267
2018
Q2
$8.61M Buy
29,709
+1,292
+5% +$363K 0.12% 119
2018
Q1
$7.78M Buy
28,417
+4,539
+19% +$1.41M 0.1% 134
2017
Q4
$7.61M Buy
23,878
+2,099
+10% +$673K 0.1% 138
2017
Q3
$6.8M Buy
21,779
+3,617
+20% +$1.07M 0.12% 136
2017
Q2
$4.93M Buy
18,162
+3,457
+24% +$914K 0.09% 153
2017
Q1
$4.02M Sell
14,705
-52,398
-78% -$14.8M 0.08% 170
2016
Q4
$19M Sell
67,103
-4,988
-7% -$1.48M 0.43% 58
2016
Q3
$22.6M Sell
72,091
-6,038
-8% -$1.79M 0.47% 52
2016
Q2
$18.9M Buy
78,129
+3,122
+4% +$823K 0.49% 51
2016
Q1
$19.5M Sell
75,007
-17,473
-19% -$4.62M 0.53% 48
2015
Q4
$28.3M Buy
92,480
+10,511
+13% +$3.02M 0.94% 26
2015
Q3
$23.9M Sell
81,969
-3,049
-4% -$1.01M 0.98% 24
2015
Q2
$34.3M Sell
85,018
-214
-0.3% -$85.9K 1.1% 24
2015
Q1
$36M Sell
85,232
-26,737
-24% -$10.5M 1.22% 22
2014
Q4
$38M Buy
111,969
+41,427
+59% +$13.4M 1.38% 24
2014
Q3
$23.3M Sell
70,542
-16,318
-19% -$5.38M 0.84% 40
2014
Q2
$27.4M Buy
86,860
+83,231
+2,293% +$25.1M 0.61% 43
2014
Q1
$1.11M Buy
3,629
+2,877
+383% +$913K 0.03% 233
2013
Q4
$211K Buy
+752
New +$195K 0.01% 410

Other funds holding BIIB

Mirae Asset Global Investments's BIIB Position: Q2 2026 in Review

Mirae Asset Global Investments increased its Biogen (BIIB) stake by 46% in Q2 2026, buying an estimated $3.54M and bringing the position to 58,746 shares worth $12.7M. The position accounts for 0.02% of the portfolio, ranked #405.

Mirae Asset Global Investments first reported a position in BIIB in Q4 2013 and has held it in 51 quarters since. The position peaked at $52.5M in Q4 2022. 430 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Mirae Asset Global Investments held 58,746 shares of Biogen worth $12.7M as of Q2 2026.
  • Mirae Asset Global Investments bought 18,508 Biogen shares in Q2 2026, an estimated $3.54M.
  • Biogen made up 0.02% of Mirae Asset Global Investments's portfolio in Q2 2026, its #405 holding.
  • Mirae Asset Global Investments first reported a position in Biogen in Q4 2013 and has held it in 51 quarters since.
  • Mirae Asset Global Investments's Biogen position peaked at $52.5M in Q4 2022.
  • 430 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.